SCHEMBL4001967

SCHEMBL4001967

CCOC(=O)c1cc(S(=O)(=O)NC)c(Cl)cc1OCC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
LMNA P02545 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
APP P05067 3/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
BAZ2B Q9UIF8 1/20 0.42
BAZ2A Q9UIF9 1/20 0.42
AURKA O14965 1/20 0.42
AURKB Q96GD4 1/20 0.42
IKBKB O14920 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4001211 0.88 CA1 (0.45) KMT2ACA1CA2CA12CA9
SCHEMBL4003078 0.88 CA1 (0.45) KMT2ACA1CA2CA12CA9
SCHEMBL4005117 0.87 HTT (0.44) KMT2ACA1CA2CA12CA9
SCHEMBL4001527 0.82 TSHR (0.56) KMT2ACA1CA2CA12CA9
SCHEMBL3999221 0.79 ALDH1A1 (0.62) KMT2ALMNAKDM4EHTTTDP1
SCHEMBL1546453 0.79 POLB (0.42) KMT2ALMNAKDM4EGAAHTT
SCHEMBL4006356 0.78 ALDH1A1 (0.61) KMT2ALMNAKDM4EHTTTDP1
SCHEMBL1546543 0.77 TDP1 (0.46) KMT2AKDM4EGAAHTTTDP1
SCHEMBL3996272 0.76 TSHR (0.59) KMT2ALMNAHTTTDP1MEN1
SCHEMBL16962416 0.75 BAZ2B (0.48) KMT2ACA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579368-B2 Cis-imidazolines HOFFMAN-LA ROCHE INC. (US) 2009-08-25 US disclosed
EP-1861376-A1 CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS F. Hoffmann-Roche AG (CH) 2007-12-05 EP disclosed
WO-2006097261-A1 CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-21 WO disclosed
US-20060211693-A1 Cis-imidazolines FOTOUHI NADER 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211693-A1 Cis-imidazolines TP53, MDM2, CDC25C KMT2A 4003/4885CA1 2178/4885CA2 994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.